The Future of Monoclonal Antibody Therapeutics - Innovation in antibody engineering, key growth strategies and forecasts to 2011

The market for therapeutic monoclonal antibodies (mAbs) is one of the most dynamic sectors within the pharmaceutical industry; next generation antibodies are forecast to drive the market towards the $30 billion mark by 2011 due to a high level of innovation in early-stage discovery and several potential nichebusters set to launch in the next 5 years. ‘The Future of Monoclonal Antibody Therapeutics: Innovation in antibody engineering, key growth strategies and forecasts to 2011’ is a unique report that combines up-to-date analysis of the current antibodies market with detailed insights into therapeutic, technology, discovery and drug delivery trends set to shape the market in the next 5 years and beyond. Gain access to the most comprehensive data on the antibody market and take advantage of exclusive insights into research trends from early stage discovery to marketed drugs.

This report provides:

Up-to-date global sales data with a comprehensive examination of key brands and detailed analysis of market dynamics, enabling you to analyze the competition and identify the critical success factors behind today’s leading brands.

Forecasts of current marketed antibodies and all pipeline drugs predicted to launch before 2011, with a detailed examination of the factors influencing future sales, ensuring that you implement strategies to optimize future revenue streams.

The latest innovation trends in antibody discovery platforms, antibody engineering and non-invasive drug delivery, to guarantee that you stay up-to-date with recent developments and identify lucrative areas of investment.

In-depth company profiles of the leading drug developers and technology innovators in the market including Genentech, MedImmune, XOMA and Crucell, providing a comprehensive view of your competitors.

Therapy area analysis of forecasted antibody sales, including inflammatory disorders, oncology and infectious disease, allowing you to identify areas poised for growth.

Alliance and M&A information from MedTRACK, including key acquisitions made by AstraZeneca, Novartis and Amgen, enabling you to understand the changing antibody market.

Gain access to the most comprehensive data on the antibody market and take advantage of exclusive insights into research trends from early stage discovery to marketed drugs.

July 2006, PDF
Table of Contents
Full Table of Contents (PDF)
Price: $2,875.00 / GBP1,437.50